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https://doi.org/10.1016/j.stemcr.2019.12.010SUMMARYRAG2 severe combined immune deficiency (RAG2-SCID) is a lethal disorder caused by the absence of functional T and B cells due to a
differentiation block. Here, we generated induced pluripotent stem cells (iPSCs) from a RAG2-SCID patient to study the nature of the
T cell developmental blockade. We observed a strongly reduced capacity to differentiate at every investigated stage of T cell develop-
ment, from early CD7CD5 to CD4+CD8+. The impaired differentiation was accompanied by an increase in CD7CD56+CD33+ nat-
ural killer (NK) cell-like cells. T cell receptor D rearrangements were completely absent in RAG2SCID cells, whereas the rare T cell
receptor B rearrangements were likely the result of illegitimate rearrangements. Repair of RAG2 restored the capacity to induce
T cell receptor rearrangements, normalized T cell development, and corrected the NK cell-like phenotype. In conclusion, we succeeded
in generating an iPSC-based RAG2-SCID model, which enabled the identification of previously unrecognized disorder-related T cell
developmental roadblocks.INTRODUCTION
Severe combined immune deficiency (SCID) is a life-threat-
ening disorder caused by a defective acquired immune sys-
tem due to the absence of functional T cells (Fischer, 2000).
In addition to T cells, SCID patients sometimes lack B cells
and/or natural killer (NK) cells depending on the underly-
ing genetic mutations. Milder forms of SCID can also occur
as a consequence of hypomorphic mutations. One sub-
group of SCID patients, accounting for approximately
30% of the SCID cases, lacks both T and B cells (Gaspar
et al., 2013). Mutations causing TnegBneg SCID most often
affect genes that play a role in the rearrangement of the B
cell receptor (BCR) and T cell receptor (TCR) loci, such as
recombination activating genes (RAG) RAG1 and RAG2,
DCLRE1C, and PRKDC (Dvorak and Cowan, 2010). RAG1
and RAG2 proteins form a tetrameric complex of two
RAG1/RAG2 heterodimers, of which one is bound to a
12-recombination signal sequence (RSS) and one to a
23-RSS in the V-D-J regions of the BCR and TCR loci. The
tetrameric RAG complex catalyzes the pairwise cleavage
of the RSSs, which are connected through non-homolo-
gous end joining, creating the huge V-D-J diversity that
underlies the enormously diverse immune repertoire
(Notarangelo et al., 2016).300 Stem Cell Reports j Vol. 14 j 300–311 j February 11, 2020 j ª 2019 The
This is an open access article under the CC BY license (http://creativecommoMost of our knowledge of the defects in T cell develop-
ment in SCID has been gathered from gene-knockout
studies in mice. However, the differentiation of human
T cells follows a slightly different route compared with
that of murine T cells (Blom et al., 1999; Dik et al., 2005;
Hao et al., 2008; Weerkamp et al., 2006). To fully under-
stand human SCID, and to study therapeutic interven-
tions, an accessible model that faithfully reflects human
SCID is required. Modeling human SCID can be performed
in vitro by culturing primary CD34+ SCID hematopoietic
stem/progenitor cells (HS/PCs) on a layer of OP9 cells
that express the Notch ligands delta-like 1 (DLL1) or
delta-like 4 (DLL4) (Six et al., 2011) or in vivo by transplan-
tation of primary long-term repopulating CD34+ SCID he-
matopoietic stem cells (HSCs) into immune-deficient
NOD-SCID common g/ (NSG) mice (Wiekmeijer et al.,
2016). Wiekmeijer and colleagues transplanted HSCs
from SCID-X1, IL7R-SCID, and DCLRE1C-SCID patients
into NSG animals and observed an earlier block in T cell
development than anticipated on the basis of gene expres-
sion profiles during human T cell development and corre-
sponding mouse knockouts. This study highlighted that
human SCIDmodels are required to investigate the precise
underlying developmental defect. However, these experi-
ments fully relied on the availability of primary SCID HS/Authors.
ns.org/licenses/by/4.0/).
Figure 1. Generation of RAG2SCID and RAG2 Repaired iPSCs
(A) Illustration of the mutant RAG2 p.R148X that causes RAG2-SCID. PHD, plant homology domain.
(B) Percentages of different B cell populations found in the bone marrow of healthy donors of <5 years (upper bar) and of the RAG2-SCID
patient with the homozygous mutation depicted in (A) (lower bar).
(C) Fluorescence microscopy analysis of the pluripotency markers NANOG and SSEA4 in one of the generated RAG2SCID iPSC clones.
(D) Analysis of the capacity of the generated RAG2SCID iPSCs to spontaneously differentiate into derivatives of the three germ layers (AFP,
endoderm; TUBB3, ectoderm; CD31, mesoderm) by fluorescence microscopy.
(E) Schematic illustration of the strategy to repair the RAG2 mutation using homology-directed repair.
(F) RAG2 sequence analysis of RAG2SCID and a repaired RAG2C iPSC clone (RAG2C1).
Scale bars represent 100 mm.PCs, which is very restricted due to the rarity of the disorder
as well as the wide range of mutations leading to different
phenotypes.
Pluripotent stem cells (PSCs) provide a good alternative to
model SCID, ashumanPSCs canbedifferentiated intoTcells
in vitro (Themeli et al., 2013; Timmermans et al., 2009) and
in vivo (Galicetal., 2009).ArtificialhumanPSCscanbegener-
ated from somatic cells by the overexpression of factors that
reset theepigeneticprogramof somaticcells into thatofPSCs
(Takahashi et al., 2007; Yu et al., 2007). These so-called
induced PSCs (iPSCs) have been successfully used to model
SCID-X1 (Menon et al., 2015), JAK3-SCID (Chang et al.,
2015), Wiskott-Aldrich syndrome (Laskowski et al., 2016),
andRAG1-SCID (Brauer et al., 2016). Since the genetic defect
that causes SCID determines the exact stage at which T cell
development is stagnated , other SCID disorders should be
investigated as well. In addition, the consequences of such
a block for the differentiation into other cell types has not
been addressed in great detail. Thus it is essential to deter-
mine towhat extent human iPSC-based SCIDmodelsmimic
other available SCID models by covering a wide variety of
SCID mutations and corresponding phenotypes.
We generated iPSCs from a SCID patient with a homozy-
gous RAG2 null mutation and demonstrate that RAG2-defi-cient iPSCs have defects throughout every step of T cell
development, starting from one of the earliest T-lymphoid-
committed stages. The most prominent partial arrests are
located at the transition from CD7+CD5 cells into
CD7+CD5+ T cells and subsequent differentiation steps. In-
hibitedTcell differentiation is accompaniedbya fate shift to-
ward NK cell-like CD7CD56+CD33+ cells. Repair of the
mutant RAG2 gene by homologous recombination restored
the differentiation phenotype as illustrated by a normal
number ofCD4+CD8+double-positive (DP)Tcellswithpoly-
clonal TCRd (TCD) and TCRb (TCB) rearrangements.RESULTS
Generation of RAG2-SCID iPSCs and Isogenic Control
iPSCs
We generated iPSCs from a female RAG2-SCID patient with
a homozygous nonsense mutation (p.R148X) in RAG2
(Figure 1A) by transduction of the patient’s dermal fibro-
blasts with a lentiviral vector expressing codon-optimized
OCT4 and KLF4, SOX2, and MYC (Warlich et al., 2011).
The selected RAG2-SCID patient demonstrated a complete
SCID phenotype indicated by the virtual absence ofStem Cell Reports j Vol. 14 j 300–311 j February 11, 2020 301
B and T cells in the peripheral blood (leukocyte count
<0.013 109/L) and a block in precursor B cell differentiation
before the pre-B-II cell stage (Figure 1B). TheNK cell count of
0.213 109/L was normal, indicative of a TnegBnegNK+ SCID.
The generated iPSC clones expressed the pluripotency
markers NANOG, OCT3/4, SSEA4, and TRA1-81 (Figures
1C and S1A) and could spontaneously differentiate into
the three germ layers (Figures 1D and S1B).We did not iden-
tify very large differences in the hemogenic differentiation
potential of the different clones upon coculturing with
OP9 cells. The percentage of CD31+CD34+ DP cells ranged
from 0.4% to 1.7%, which was lower than with control H1
embryonic stem cells (ESCs) (3.9%) but similar to skin-
derived iPSCs from a healthy donor (1.5%). This is in line
with the observation that genetic background differences
are themajor contributors tovariations in thedifferentiation
potential of iPSC lines (Kajiwara et al., 2012; Kilpinen et al.,
2017). We removed the inserted, single-copy, provirus from
oneof theRAG2SCIDclones throughhc.fiber50.FLPeadeno-
viral vector-mediated FLPe expression to avoid a potential
position effect of the integrated provirus (Figures S1D and
S1E). Karyotype analysis of the generated iPSC clones did
not reveal any gross genomic aberrations (Figure S1I). In
addition, the pluripotent potential of the RAG2SCID iPSC
cloneswas demonstrated bydifferentiation into ectodermal,
endodermal,andmesodermalderivatives invivo (FigureS1C).
Subsequently, the RAG2 mutation was repaired through
conventional homologous recombination (Figures 1E, 1F,
S1F, and S1G). To ensure that RAG1 and RAG2 transcription
fully mirrored RAG expression in unmodified, wild-type
cells, the intergenic PGKpuromycinDTK selection cassette
was removed from one of the repaired iPSC clones by
fiber5.CRE adenoviral vector-mediated CRE recombination
(Figure S1H). The pluripotent nature and genomic integrity
of the repaired RAG2 iPSC clones (RAG2C) were
reconfirmed before further assessment of the phenotype
(Figures S1C and S1I).Early Hematopoietic Differentiation Is Unaffected in
RAG2-SCID iPSCs
First we wished to compare the capacity of the RAG2
mutant (RAG2SCID) and the RAG2 repaired (RAG2C) iPSC
lines to differentiate into early hemogenic endothelial cells
and committed hematopoietic progenitors. Early hemo-
genic colonies from RAG2SCID and RAG2C were compara-
ble inmorphology (Figure S2A). Analysis of the endothelial
marker CD31 (Lertkiatmongkol et al., 2016), the hemato-
poietic and endothelial progenitor marker CD34 (Ditadi
and Sturgeon, 2016), the early hematopoietic commitment
marker CD43 (Vodyanik et al., 2005), and the universal
hematopoietic marker CD45 at day 9 and day 12 of he-
matopoietic differentiation showed similar hemogenic302 Stem Cell Reports j Vol. 14 j 300–311 j February 11, 2020and committed hematopoietic populations in RAG2SCID,
RAG2C, and control H1 ESCs (Figures 2A, 2B, and S2B).
RAG2-SCID Cells Are Impaired in T Cell Development
Since the RAG2 defect likely affects T cell development,
we investigated the differentiation of RAG2SCID iPSCs
into T cells using the OP9-DLL1 coculture system (The-
meli et al., 2013). In Rag2 knockout mice, the T cell differ-
entiation block is located in CD4-CD8-CD44-CD25+
(DN3) cells, yielding dramatically reduced numbers of
CD4+CD8+ DP T cells (Shinkai et al., 1992). In the three
RAG2SCID iPSC clones, CD4+CD8+ DP T cells were
sparsely observed, in contrast to the repaired RAG2C
iPSC clones and the gold standard H1 ESCs (Figures 3A,
3B, and S3). Immature human T cells are first CD7+CD5
and subsequently become CD7+CD5+ prior to differentia-
tion into immature single-positive (ISP) cells. The
CD7+CD56 lymphoid population, consisting of
CD7+CD5 as well as CD7+CD5+ cells, was significantly
reduced in RAG2SCID cells, indicating that the RAG2
mutant cells generated CD7+ lymphoid cells less effi-
ciently in comparison with H1 and RAG2C cells (Figures
3A, 3C, and S3). Dissection of the CD7+ lymphoid popu-
lation showed that the RAG2SCID cells are impaired in
becoming CD7+CD5+ cells and in differentiating further
into CD4+CD8+ DP T cells (Figures 3A, 3D, 3E, and S3).
Thus, it appears that RAG2SCID cells are hindered in their
progression through different stages of T cell develop-
ment, with the strongest arrest located at the CD7+CD5+
stage.
RAG2SCID Tand NK Cells Do Not Undergo Legitimate
TCR Rearrangements
Since RAG2 is, together with RAG1, responsible for the
generation of double-strand breaks (DSBs) at the border
of an RSS required for the rearrangement of the different
TCR segments, we investigated the presence and features
of TCB rearrangements by GeneScan analysis (Brugge-
mann et al., 2004). Whereas H1- and RAG2C-derived cells
undergo normal TCB rearrangement as shown by the
presence of polyclonal T cell populations represented by
the Gaussian distribution of Vb-Jb2(2.2, 2.6, 2.7) fragment
sizes, we could not detect any Vb-Jb2 rearrangements in
RAG2SCID CD7+ CD56 cells (Figures 4A and S4A). Never-
theless, the presence of a small fraction of CD4+CD8+ DP
RAG2SCID cells in the iPSC-derived T cell differentiation
cultures indicates that a few RAG2SCID cells could un-
dergo successful positive selection, which is instigated
by TCB rearrangements. Therefore, we also investigated
the presence of Vb-Jb1 rearrangements. We observed
very few Vb-Jb1 rearrangements in RAG2SCID cells (Fig-
ure 4B), of which a proportion was of an unexpected
size (predicted sizes 240–285 bp). This indicates that the
Figure 2. Similar Capacities of RAG2SCID and RAG2C iPSCs to Differentiate toward Early Hematopoietic Cells In Vitro
Flow cytometric analysis of hemogenic and hematopoietic cell types (A) at day 9 and (B) at day 12 of in vitro hematopoietic differentiation
of H1 (top), RAG2SCID (middle), and RAG2C cells (bottom). One plot is a representative of the results of three independent experiments.identified rearrangements are rather the result of the
repair of rare spontaneous DSBs than of genuine RAG-
driven, RRS-based recombination. To further prove the
absence of legitimate rearrangements we checked for the
presence of immature TCD rearrangements in developing
RAG2SCID and RAG2C T cells. The first rearrangement
during T cell development, also for ab T cells, is the
Dd2-Dd3 rearrangement in the TCD locus. Dd2-Dd3 rear-
rangements are already observed in very early
CD34+CD38 thymocytes and peak in CD34+CD38+ thy-
mocytes (Dik et al., 2005). Dd2-Dd3 rearrangements are
subsequently followed by immature Vd2-(Dd1-Dd2)-Dd3
rearrangements. We observed Dd2-Dd3 and Vd2-Dd3, as
well as more mature Vd1-Dd3, TCD rearrangements in
sorted CD7+CD56CD4CD8 RAG2C cells but not in
sorted CD7+CD56 RAG2SCID T cells or in RAG2C iPSCs
(Figures 4C and S4B). Comparison of the TCD rearrange-
ments in unsorted populations of differentiated RAG2C
cells and H1-derived cells showed very similar Dd2-Dd3,
Vd2-Dd3, and Vd1-Dd3 profiles, in terms of both clonality
and size distributions (Figure 4D). Of note, Dd2-Dd3 rear-
rangements are more diverse in primary human ISP cells(Figure S4B). Cells that are similar to T cells and are gener-
ated in, among others, the thymus are NK cells (Narni-
Mancinelli et al., 2011). In particular, CD56bright cells
represent an intrathymic NK cell population that is
responsive to interleukin-7 (IL-7) (Michaud et al., 2010;
Vosshenrich et al., 2006). One NK cell subpopulation,
which is thought to have higher fitness than the others,
at least in mice, consists of NK cells that express RAG dur-
ing a certain stage of their development (Karo et al.,
2014). As a consequence, a proportion of NK cells, also
in men, exhibits TCD rearrangements, in particular imma-
ture Vd2-Dd3 rearrangements (Fronkova et al., 2005).
Since the OP9-DLL1 differentiation protocol used sup-
ports the development of CD7+CD56+ NK cells (Zeng
et al., 2017) (Figure 3A), we checked TCD rearrangements
in CD7+CD56+ cells derived from RAG2SCID and RAG2C
iPSCs. Vd2-Dd3 rearrangements were prominent in
RAG2C CD7+CD56+ cells, confirming the results found
in primary human NK cells (Figure 4E). We could also
detect Vd1-Dd3 rearrangements in RAG2C CD7+CD56+
cells, whereas the most immature Dd2-Dd3 rearrange-
ments were largely absent (Figure 4E). In contrast,Stem Cell Reports j Vol. 14 j 300–311 j February 11, 2020 303
Figure 3. Impaired Differentiation of RAG2SCID iPSCs into T Cells In Vitro
(A) Flow cytometric analysis of the differentiation of H1 (top), RAG2SCID (middle), and RAG2C (bottom) cells into the T lineage.
(B–D) (B) Plotted percentages of generated CD4+CD8+ DP T cells, (C) early CD7+ lymphoid cells, and (D) CD7+CD5+ cells.
(E) Fold decrease in the differentiation of RAG2SCID iPSCs into T lineage cells compared with the repaired RAG2C iPSCs. Results in (B), (C),
(D), and (E) are from three independent experiments using 3 RAG2SCID and 2 RAG2C clones. Averages + standard deviations are shown. *p <
0.05, ***p < 0.001RAG2SCID CD7+CD56+ cells did not have any TCD rear-
rangements (Figure 4E). These results highlight that
RAG2SCID cells are indeed unable to properly recombine
the TCR loci in contrast to repaired RAG2C cells.
Differentiation of RAG2-SCID Cells Is Skewed toward
NK Cell-like Cells
Next, we wished to investigate whether the reduction in
CD7+ lymphoid progenitors in RAG2SCID cultures was
caused by a fate switch of early lymphoid progenitor cells
toward cell types that do not require functional TCR rear-
rangements for their development. Since the OP9-DLL1
differentiation protocol used supports efficient CD56+ NK
cell development, we zoomed in on the CD56+ popula-
tions. We did not observe alterations in the percentages
of CD7+CD56+ cells generated from RAG2SCID, RAG2C,
or H1 ESCs (Figure 5A). Instead, we found a significant
increase in the generation of RAG2SCID CD7CD56+ cells
(Figure 5B). To our knowledge the only described
CD7CD56+ cells are monocytic/dendritic cell (DC)-like
cells that are positive for CD13, CD33, CD123, and HLA-
DR (Milush et al., 2009).We analyzed theCD7CD56+ pop-
ulation for the expression of a variety of DC, myeloid cell,
and NK cell markers by flow cytometry. The iPSC-derived
CD7CD56+ population was largely positive for CD33,304 Stem Cell Reports j Vol. 14 j 300–311 j February 11, 2020whereas any other tested monocytic cell, DC, and NK cell
markers were absent (Figures 5C, S5A, and S5C). In
contrast, the CD7+CD56+ cells showed a typical NK cell
profile, as they expressed CD16, which is commonly found
on NK cells, and the NK cell marker NKG2D (Figures S5B
and S5C). Since myeloid cell and DC markers were absent,
we wondered whether the CD7CD56+CD33+ cells would
respond to NK cell-specific stimuli. CD7CD56+ cells stim-
ulated with IL-12, IL-15, and IL-18 produced similar levels
of IFN-g, TNF-a, and GM-CSF compared with iPSC-derived
typical CD7+CD56+ NK cells (Figure 5D). Only the ‘‘mutu-
ally exclusive’’ production of IL-10 and IL-13 allowed
discrimination of the CD7CD56+ and CD7+CD56+ popu-
lations (Figure 5D). In conclusion, our results suggest that
inhibition of T cell development by RAG2 deficiency leads
to a skewed differentiation toward CD7CD56+CD33+ NK
cell-like cells.DISCUSSION
SCID is caused by a wide variety of mutations and has been
mainly investigated using mouse knockout models. It has
become evident that human SCID models using mouse
knockouts of the affected gene do not represent the human
Figure 4. Defective T Cell Receptor Rearrangements in RAG2SCID Cells Are Rescued by Repair of RAG2
(A) GeneScan analysis of TCB (Vb-Jb2) rearrangements in whole populations (H1 and RAG2C) and in sorted CD7+CD56 cells (RAG2SCID).
(B) GeneScan analysis of TCB (Vb-Jb1) rearrangements in sorted CD7+CD56 cells (RAG2SCID).
(C) GeneScan analysis of TCD rearrangements in sorted CD7+CD56 cells (RAG2SCID) and CD7+CD4CD8CD56 cells (RAG2C).
(D) GeneScan analysis of TCD rearrangements in whole populations (H1 and RAG2C).
(E) GeneScan analysis of TCD rearrangements in CD7+CD56+ cells of RAG2SCID and RAG2C. Fragment length (TCD 150–268 bp and TCB 220–
289 bp) is plotted on the x axis. All samples analyzed were from week 4–5 differentiation cultures.situation very well, likely because human T cell develop-
ment is different from that in mice (Blom et al., 1999;
Dik et al., 2005; Hao et al., 2008; Weerkamp et al., 2006).
The best human SCID model to date involves the trans-
plantation of CD34+ SCID HS/PCs into NSG animals
(Wiekmeijer et al., 2016). However, the availability of
CD34+ HS/PCs from SCID patients is very limited due to
the rarity of the disorder and the wide range of different
SCID mutations. Therefore an alternative SCID modeling
system is warranted. iPSCs derived from SCID patients
have shown promise, but due to the wide variety of SCID
mutations and corresponding phenotypes, additional
studies are required to evaluate iPSC-based SCIDmodeling.
Using RAG2-SCID iPSCs we observed phenotypic
differences with the reported phenotype of Rag2 knockout
mice (Shinkai et al., 1992). RAG2SCID iPSC-derived
cells showed a partial arrest at every stage of T cell develop-
ment, ultimately leading to very few CD4+CD8+ DP
T cells (Figure 6). The transitions from CD7+CD5 into
CD7+CD5+ cells and from CD7+CD5+ into CD4+CD8+
T cells were most profoundly impaired in RAG2SCID. Our
results are in line with the results obtained from the trans-
plantation of primary bone marrow DCLRE1C-SCID
CD34+ hematopoietic cells into NSG mice, where a full
block at the CD7+CD5+ stage and a reduced differentiation
into CD7+CD5 as well as CD7+CD5+ cells were observed(Wiekmeijer et al., 2016). Artemis, which is encoded by
DCLRE1C, is involved in opening of the hairpins formed
at both nicked RSSs, which are required for V(D)J recombi-
nation (Ma et al., 2002). As a consequence the pathogenic
phenotypes of RAG-SCID and DCLRE1C-SCID are very
similar (Dvorak and Cowan, 2010). Despite the lack of
functional Artemis the absence of CD4+CD8+ DP T cells,
TCB and TCD rearrangements were found in the arrested-
DCLRE1C-SCID cells, possibly because the hairpins were
resolved by a repair mechanism other than Artemis (Wiek-
meijer et al., 2016). In contrast, RAG2SCID iPSC-derived
cells showed only very rare TCB rearrangements, yet imma-
ture Dd2-Dd3 rearrangements were undetectable. From our
data it could be argued that immature TCD rearrange-
ments, which are already detected in the earliest
CD34+CD38 T progenitor cells (Dik et al., 2005),
contribute to a more efficient initiation and progression
of T cell development. A genome-wide association study
has indeed revealed that a single-nucleotide polymorphism
(SNP)within theDd2-Dd3 region influences Tcell numbers,
particularly of early CD4CD8 thymocytes, highlighting
the importance of the region between the Dd2 and the
Dd3 segments (Clave et al., 2018). Since we did not observe
a full block at the CD7+CD5+ stage, this would indicate that
human SCID models based on the coculture of SCID iPSCs
and OP9-DLL cells are more lenient. A recent study usingStem Cell Reports j Vol. 14 j 300–311 j February 11, 2020 305
Figure 5. An Increase in CD7CD56+CD33+ NK Cell-like Cells in RAG2SCID iPSC Differentiation Cultures
(A and B) (A) Plotted percentages of iPSC-derived CD7+CD56+ NK cells and (B) CD7CD56+ cells.
(C) Flow cytometric analysis of CD33 and CD14 (myeloid) and CD16 and NKG2D (NK cell) expression in the CD7CD56+ population.
(D) Production of cytokines by CD7CD56+ and CD7+CD56+ cells measured after 20 h of stimulation with IL-12, IL-15, and IL-18. Results are
from at least three independent experiments. Averages + standard deviations are shown. **p < 0.01.RAG1-SCID iPSCs has suggested that multiple T cell waves
exist in vitro and that only a longer T cell differentiation
period of 4–5 weeks better reflects the in vivo phenotype
(Brauer et al., 2016). In our study we observed very few
ISP and DP cells in RAG2-SCID cultures, irrespective of dif-
ferentiation length. Possibly this difference is explained by
the severity of the mutation and/or the affected gene. In
addition, the transition from CD3 DP to CD3+ DP cells
may be affected in RAG2-SCID patients, but this remains
to be studied. Nevertheless, we describe and rescue similar
blocks at the CD7+CD5 and CD7+CD5+ stages of T cell
development, as reported in the RAG1-SCID iPSC-based
model.
The absence of TCD rearrangements and the presence of
sporadic Vb-Jb1 rearrangements, of which a fraction
yielded smaller PCR fragment sizes than expected, indicate
that the sparse TCB rearrangements found in RAG2SCID T
lymphoid cells are likely the result of extremely rare
random deletions that occurred in only very few cells.
These illegitimately rearranged cells are able to bypass the
b-selection checkpoint, allowing clonal expansion until
the CD4+CD8+ DP stage. At this stage TCRA needs to rear-
range, which is likely to fail in RAG2mutant cells, resulting
in the lack of mature CD4 and CD8 single-positive (SP)
cells. In addition to the T cell phenotype, we observed a
strong increase of CD7CD56+CD33+ cells that do not ex-
press other common myeloid lineage, DC, and NK cell
markers. However, the observed NK cell-specific cytokine
production upon stimulation implies an NK cell-like func-
tion. NK cells are generated in multiple tissues, among
which is the thymus (Yu et al., 2013). In particular306 Stem Cell Reports j Vol. 14 j 300–311 j February 11, 2020CD56bright cells are believed to represent thymic NK cells
(Vosshenrich et al., 2006). Recently, a multicenter study
showed that CD56bright NK cells are strongly enriched in
the periphery of RAG-SCID patients and that these cells
have a rather immature phenotype (Dobbs et al., 2017).
It would be interesting to see whether the CD56bright
NK cells of RAG-SCID patients encompass a
CD7CD56+CD33+ NK cell-like subset as well. Although
the human data contrast with the more mature phenotype
of NK cells found in Rag2-null mice (Karo et al., 2014), it is
obvious that the absence of either RAG gene has an effect
on theNK cell population. The expression of RAGproteins,
somewhere along the route of NK cell differentiation, pro-
duces TCD rearrangements in a subset of NK cells. In partic-
ular, immature Vd2-Dd3 rearrangements are frequently
found in NK cells in humans (Fronkova et al., 2005). Like-
wise, we identified predominantly Vd2-Dd3 rearrange-
ments in RAG2-corrected CD56+CD7+ NK cells, but not
in RAG2SCID NK cells. This reconfirms the rearrangement
deficiency in RAG2SCID cells and highlights that the
applied iPSC-based model system reflects the in vivo situa-
tion very well.
In conclusion, we present a human RAG2-SCID model
that better recapitulates the mutant RAG2 phenotype
than the equivalent mouse knockout, as we could reveal
previously unrecognized blocks in T cell development.
Although direct comparison with other in vivo human
SCID modeling systems is still needed, this model likely
provides opportunities to link specific mutations to the
wide variety of human SCID phenotypes and to evaluate
the ability of drugs to rescue the observed phenotype.
Figure 6. Schematic Illustration of the
Impaired T Lineage Differentiation in
RAG2-SCID
On the basis of our findings we propose
partial developmental arrests at several
stages of T cell development. The extent of
inhibition is represented by line width. As a
consequence of the impaired capacity to
progress through T cell development,
CD7CD56+CD33+ NK cell-like cells are likely
generated from early CD7 or CD7+ pro-
genitors.EXPERIMENTAL PROCEDURES
Generation and Characterization of iPSCs
Passage three fibroblasts from a female RAG2-SCID patient were re-
programmed into iPSCs as described elsewhere (Dambrot et al.,
2013). The patient contained a normal number ofNK cells in the pe-
ripheral blood,whereas B andTcellswere <0.013 109/L. In thebone
marrow therewas a complete block prior to the cytoplasmic Igm-pos-
itive pre-B-II stage. In brief: 2 3 104 human fetal fibroblasts were
transducedat anefficiencyof <10%with themulticistronic lentiviral
vector LV.RRL.PPT.SF.hOKSM.idTomato.-preFRT (Warlich et al.,
2011) in a 12-well plate. One day after transduction, fresh human
fibroblast medium (DMEM/F12, 10% fetal bovine serum [FBS]
[Thermo Fisher Scientific], non-essential amino acids [NEAA]
[Thermo Fisher Scientific], 100 mM b-mercaptoethanol [Sigma], and
penicillin/streptomycin) was added. Cells were harvested using 13
trypsin/EDTA (Thermo Fisher Scientific) 6 days posttransduction,
and13104 cellswere seededonto irradiatedCD1murineembryonic
fibroblasts (MEFs) in a 10-cm Petri dish (Greiner) coated with 0.1%
gelatin (Sigma) in PSC growthmedium (DMEM/F12 [Thermo Fisher
Scientific], 20% knockout replacement serum [KRS] [Thermo Fisher
Scientific], 10 ng/mL human basic fibroblast growth factor [bFGF]
[Peprotech], NEAA [Thermo Fisher Scientific], 100 mM b-mercaptoe-
thanol [Sigma], and penicillin/streptomycin [Thermo Fisher Scienti-
fic]). Themediumwas replaced every other day until the appearance
of human ESC-like colonies. iPSC clones were manually picked and
further expanded on ESC-qualified Matrigel (Becton Dickinson
[BD])-coated 6-well plates inmTESR1 (STEMCELLTechnologies). Af-
ter five passages in mTESR1 the clones were also adapted to feeder
conditions and further cultured asdescribedbelow. For a full descrip-
tion of the characterization protocol we refer to previous studies
(Chen et al., 2017; Dambrot et al., 2013). Selected clones were
analyzed for the expression of pluripotencymarkers using immuno-
staining with primary antibodies recognizing OCT3/4 (1:100; Santa
Cruz Biotechnology, cat. no. sc-5279), SSEA4 (1:30; Biolegend, cat.
no. 330402), TRA1-81 (1:125; Biolegend, cat. no. 330702), and
NANOG (1:500; R&D Systems, cat. no. 963488) and Alexa 488-,
Alexa 568-, and Alexa 647-conjugated secondary antibodies (1:500;
Thermo Fisher Scientific). Differentiation into three-germ-layer
derivatives was assessed by spontaneous differentiation in MEF
medium for 3 weeks and subsequent detection of expression of
germ-layer-specificmarkers using immunofluorescencemicroscopy.
Antibodies against AFP (1:25; Quartett, cat. no. 2011200530), CD31(1:100; Dako, cat. no. M0823), and TUBB3 (1:4,000; Covance, cat.
no. MMS-435P) were used. Secondary antibodies were conjugated
with either Alexa 488 or Alexa 568 (1:500; Thermo Fisher Scientific).
The genome of the clones was analyzed with combined binary ratio
labeling (COBRA).
The number of provirus insertions was determined by Southern
blot analysis using 10 mg of PaeI-restricted genomic DNA and a
NotI/HincII fragment containing the RRE part of the lentiviral re-
programming vector as probe.
To generate teratomas 13 106 cells were injected subcutaneously
into 8- to 12-week-old immunocompromised female Rag2/mice.
Teratomas were isolated 10–16 weeks postinjection. Teratomas
were fixed in 4% paraformaldehyde and, subsequently, embedded
in paraffin and sectioned. Ectodermal, endodermal, and meso-
dermal derivatives were visualized by H&E staining and standard
light microscopy.
All humanmaterials were collected according to the approval by
theMedical Ethics Committee of ErasmusMC (reference no. MEC-
2016-606) or LUMC (reference no. P08-087). The experiments
involvinghumanmaterials were done in accordancewith the prin-
ciples outlined in the Declaration of Helsinki. Animal experiments
were approved by the Animal Experiments Committee of LUMC
(reference no. 12133) and were performed following the recom-
mendations and guidelines set by LUMC and the Dutch Experi-
ments on Animals Act.
Maintenance Culture of PSCs
RAG2SCID iPSC clones (official names: LUMC043iRAG04, LUM-
C043iRAG05, LUMC043iRAG06, and LUMC043iRAG18), the re-
paired isogenic controls (LUMC043iRAGC1 and LUMC043iR-
AGC2), and the wild-type human ESC line H1 (WiCell Research
Institute) were cultured on ESC-qualifiedMatrigel (BD) in mTESR1
(STEMCELL Technologies) or on irradiated MEFs (10,000 cells/
cm2) (either CD1 [maintenance, genetic modification] or CF1 [T
cell differentiation]) on 0.1% gelatin (Sigma)-coated tissue culture
plastic in human ESC medium (HESCM) consisting of DMEM/F12
(Gibco), NEAA (Thermo Fisher Scientific), 100 mM b-mercaptoetha-
nol (Sigma), 10 ng/mL human bFGF (Peprotech), penicillin/strep-
tomycin, and 20%KRS (Thermo Fisher Scientific). Cells cultured in
mTESR1 were refed once a day and passaged once a week using
gentle cell dissociation reagent (GCDR) (STEMCELLTechnologies).
Cells cultured on feeders were refed once every other day and
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using either dispase II (Sigma) or collagenase I (Sigma) treatment.
For differentiation experiments RAG2 iPSC lines beyond passage
10 and H1 ESCs beyond passage 27 were used.
Genomic DNA Isolation
Genomic DNA was extracted from iPSC clones or differentiated
cells that were snap frozen as follows: cells were incubated in lysis
buffer containing 10mMTris-HCl (pH 8.0), 25mMEDTA (pH 8.0),
0.5% (w/v) SDS, 100 mM NaCl, and 100 mg/mL proteinase
K (Thermo Fisher Scientific) at 55C for at least 5 h, after which
the DNA was precipitated with 0.7 volumes of isopropanol. For
Southern blotting we included one phenol:chloroform:isoamyl
alcohol (25:24:1) (Sigma) extraction step prior to precipitation.
The precipitated DNA was washed once with 70% (v/v) ethanol
and dissolved in 10 mM Tris-HCl (pH 8).
Removal of Provirus
LUMC043iRAG18 was selected for removal of the inserted provi-
rus. To this end the iPSC line was first adapted to single-cell
passaging as follows. iPSC colonies were dissociated into single
cells or small clumps of cells (1–5 cells) by a 1–3 min incubation
with TrypLE select (Thermo Fisher Scientific) and replated in
50% fresh HESCM and 50% old HESCM in which the cells were
cultured in the presence of 10 mM Fasudil (LC Laboratories). Irradi-
ated CD1 MEFs were seeded on 0.1% gelatin-coated plates 1 day
before passaging. Cells were passaged when they were subconflu-
ent, i.e., iPSC colonies almost touching (either next day or after
2 days). The provirus was removed by transduction of single cells
in suspension with hcAd.FLPe.F50 adenoviral vector (Gonçalves
et al., 2008) at a multiplicity of infection (MOI) of 20 transduction
units (TU)/mL. After 1 h at 37C, single cells were seeded onto
MEFs. Removal of the provirus was determined by PCR analysis
of the genomic DNA isolated from single-cell-derived clones 11–
12 days after transduction.
Genetic Modification of RAG2SCID iPSCs
RAG2SCID iPSCs were cultured on mTESR1 and Matrigel for the
first passages. After passage 5 the iPSCs were cultured on irradiated
CD1 MEF feeders (10,000 cells/cm2) on 0.1% gelatin (Sigma)-
coated tissue culture plastic in HESCM. Prior to electroporation,
cells were adapted to single-cell passaging for at least three passages
as described above. One day prior to electroporation, cells were
passaged in the presence of 10 mM Fasudil (LC Laboratories) to
reach a subconfluent density the next day. Single cells (1.5 3
107) were electroporated with 40 mg of PvuI (Fermentas)-linearized
RAG targeting vector in 800 mL of ice-cold PBS in a 0.4 mL cuvette
(Bio-Rad) using a Bio-Rad GenePulser II electroporator (250 V,
500 mF). The targeting vector contained a 28,721 bp RAG1 and
RAG2 genomic DNA fragment from BAC RP11-669J23 (obtained
from the Sanger Institute) that was shuttled into pSuperCOS
containing RAG-recombineering sequences using pRedET (Gene-
Bridges)-mediated recombineering. To enable selection, a PCR-
amplified SbfI-LoxP.PGKpuroDelTK.LoxP-SbfI cassette was inserted
into the SbfI site in the intragenic region between RAG1 and
RAG2, generating a 50 homology arm of 12,230 bp and a 30 homol-
ogy arm of 16,491 bp. Electroporated cells were seeded onto puro-
mycin-resistant MEFs (transduced with a CMV-puro lentiviral308 Stem Cell Reports j Vol. 14 j 300–311 j February 11, 2020vector) in HESCM containing 10 mM Fasudil (LC Laboratories).
Cells were selected in HESCM containing 1 mg/mL puromycin
(Thermo Fisher Scientific) for 7 days starting 2 days after electropo-
ration. After 11–12 days colonies were numbered, and half of the
colony was collected by scraping with a pipet tip from which
genomic DNA was isolated. Correctly recombined clones were
identified by PCR amplification of themutated RAG2 regions using
Phusion polymerase (New England Biolabs), followed by PvuII
(Fermentas) restriction of the amplified fragments. The PCR frag-
ments were Sanger sequenced. The clones in which one of the
mutant RAG2 alleles was repaired were expanded and officially
named LUMC043iRAGC1 and LUMC043iRAGC2. After repair by
homologous recombination, LUMC043iRAGC1was again adapted
to single-cell passaging and the selection cassette was removed
using CRE recombinase delivery via a first-generation Ad.CRE.F5
vector at an MOI of 50 TU/mL. Cells from which the selection
cassette was removed were selected using 200 nM FIAU (Moravek)
for 5 days starting 2 days after viral transduction. Removal of the
PuroDTK marker was verified by PCR using intergenic RAG and
PGKrev primers and genomic DNA control primers (Table S1).Hematopoietic Differentiation of iPSCs
The hemogenic potential of the different iPSC clones was deter-
mined by coculturing the iPSCs (embryoid bodies [EBs]) on
confluent OP9 stroma as described elsewhere (Timmermans
et al., 2009). For comparisonof the repaired versus parentalRAG2S-
CID lines we used the StemDiff hematopoietic kit (STEMCELL
Technologies). In brief, we cut iPSC colonies (cultured on hESC-
qualified Matrigel [BD] in mTESR1) into small 50–100 mm pieces.
These pieces were collected in mTESR1 after short treatment with
GCDR (STEMCELLTechnologies) and seeded ontoMatrigel-coated
plates at a density of 4–10 pieces/cm2. Medium was changed ac-
cording the manufacturer’s instructions and cells were harvested
at day 9 and day 12 of hematopoietic differentiation using TrypLE
select (Thermo Fisher Scientific). Differentiation was determined
by flow cytometry using anti-CD31 BV605 (BD, no. 562855),
anti-CD34 PeRCPe710 (eBioscience, no. 46-0349-42), CD43-FiTC
(BD, no. 555475), and anti-CD45 V450 (BD, no. 560368). iPSCs
incubated with antibodies and unstained differentiated cells
were used as negative controls to determine the gates.
iPSCs were differentiated toward the T lymphoid lineage using a
previously described protocol (Themeli et al., 2013). Briefly, undif-
ferentiated iPSC colonies were treated with dispase and transferred
to low-attachment plates to allow the formation of EBs in Stem-
Pro-34 medium (Thermo Fisher Scientific) supplemented with
2 mM L-glutamine, 1% NEAA, 10 mM b-mercaptoethanol, 100 U/
mLpenicillin and 100ng/mL streptomycin, and 50 mg/mL ascorbic
acid (Thermo Fisher Scientific). The formation of EBs was facili-
tated by an overnight incubation in the presence of 30 ng/mL
hBMP-4 (R&D Systems [R&D]). EBs were then cultured with
hBMP-4 (30 ng/mL) (R&D) and hbFGF (5 ng/ml) (Peprotech) until
day 4 to allow for mesoderm induction. Next, hematopoietic spec-
ification and expansion were achieved in the presence of hVEGF
(20 ng/mL) (Peprotech) and a cocktail of hematopoietic cytokines
(hSCF, 100 ng/mL [R&D]; hFlt3L, 20 ng/mL; hIL-3, 20 ng/mL; and
hIL-6, 10 ng/mL [all Peprotech]). Day 9 EBs containinghematopoi-
etic progenitor cells were dissociated by treatment with Accutase
(Thermo Fisher Scientific) for 20 min, and single cells were then
seeded on OP9-DLL1 monolayers to allow for their T lymphoid
differentiation in OP9 medium (a-MEM with 20% FBS, 2 mM
L-glutamine, 1% NEAA, 10 mM b-mercaptoethanol, 100 U/mL
penicillin and 100 ng/mL streptomycin, and 50 mg/mL ascorbic
acid [all Thermo Fisher Scientific]) supplemented with
SCF, 10 ng/mL (R&D); IL-7, 5 ng/mL (Peprotech); and Flt3L,
10 ng/mL (Peprotech). Once a week cells were harvested and sub-
cultured on OP9-DLL1 monolayers. Medium was replaced once
every other day. Differentiationwas determined by flow cytometry
using the following antibodies: anti-CD1c FiTC, anti-CD4 BV650
(BD, no. 56387), anti-CD5 PE (BD, no. 561897), anti-CD7 PE-
Cy7 (eBioscience, no. 25-0079-41), anti-CD8a FiTC (BD, no.
561947), anti-CD11c PerCP-Cy5.5 (BD, no. 565227), anti-CD13
V450 (BD, no. 561157), anti-CD14 APC-Cy7 (BD, no. 557831),
anti-CD16 APC-Cy7 (BD, no. 561726), anti-CD33 BV421 (BD,
no. 562854), anti-CD43 FiTC (BD, no. 555475), anti-CD45 V450
(BD, no. 560368), anti-CD56 BV785 (Biolegend, no. 362550),
CD123 PE (BD, no. 340545), anti-CD141 APC (BD, no. 564123),
anti-HLA-DR APC-H7 (BD, no. 561358), anti-NKp46 PE (BD, no.
557991), and anti-NKG2D APC (BD, no. 562064). iPSCs incubated
with antibodies and unstained differentiated cells were used as
negative controls to determine the gates.Statistical Analyses
Statistical analyses were performed using GraphPad Prism software
version 7.0. For normal distributions two-tailed Student’s t tests
were used. A p value of <0.05was considered statistically significant.TCB and TCD GeneScan Analysis
Genomic DNA was directly isolated from frozen sorted and un-
sorted cells as described above, except the phenol extraction was
omitted. Vb-Jb rearrangements were amplified using TCRB tube
A (Invivoscribe), Amplitaq GOLD (Thermo Fisher Scientific), and
Buffer II (Thermo Fisher Scientific) according to themanufacturer’s
protocol. The TCD rearrangements were detected using a custom-
ized primer mix (Invivoscribe) containing 10 pmol of HEX Dd3-30
and Vd1, Vd2 Dd2-50 primers, Amplitaq GOLD (Thermo Fisher Sci-
entific), 2 mM MgCl2, dNTP (200 mM each), and Amplitaq GOLD
Buffer II (Thermo Fisher Scientific). DNA input was 100 ng and
PCR conditions were as follows: 7 min at 95C and 40 cycles 45 s
at 95C, 45 s at 60C, 35 s at 72C. Fragments were separated on
a 3730 DNA analyzer (Applied Biosystems), analyzed using the R
package Fragman (version 1.0.9), and plotted using R version 3.4.4.NK Cell Stimulation
Cells were isolated from umbilical cord blood or iPSC T cell differ-
entiation cultures by fluorescence-activated cell sorting on the ba-
sis of CD7 and CD56 expression. Cells were cultured in AIM Vme-
dium (no. 31035025, Thermo Fisher Scientific) containing 5%
heat-inactivated FBS without or with 10 ng/mL IL-12 (Peprotech),
10 ng/mL IL-15 (R&D), and 20 ng/mL IL-18 (MBL International) in
a 96 round-bottomwell plate at a density of 12,000 cells/well. After
20 h the supernatants were harvested after spinning the cell sus-
pension at 450 3 g and snap frozen. Medium without cells served
as baseline. Cytokine production was measured with the Bio-PlexPro Human Cytokine 27-plex Immunoassay (Bio-Rad) according
the manufacturer’s protocol.
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